Pharmaceutical interventions for obesity: A public health perspective

Diabetes, Obesity and Metabolism

Volumn 13, Issue 6, 2011, Pages 490-497

  Caveney, E ^a   Caveney, B J ^b   Somaratne, R ^a   Turner, J R ^a   Gourgiotis, L ^a  

^a IQVIA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiobesity drug; Behavioural factors; Clinical trial; Cost effectiveness; Medicines management; Obesity; Obesity therapy; Pathophysiological sequelae of obesity; Pharmaceutical interventions; Public health; Regulatory guidance

Indexed keywords

2,4 DINITROPHENOL; AMFEBUTAMONE; AMFEPRAMONE; AMINOREX; AMPHETAMINE; BENZPHETAMINE; BMS 830216; CETILISTAT; DOPAMINE RECEPTOR BLOCKING AGENT; EPHEDRA EXTRACT; FENFLURAMINE; FLUOXETINE; GSK 1521498; GSK 598809; ISOTRETINOIN; LIRAGLUTIDE; LORCASERIN; LY 377604; MAZINDOL; NEUROPEPTIDE Y; PF 04620110; PHENDIMETRAZINE; PHENTERMINE; PHENYLPROPANOLAMINE; PRAMLINTIDE; RANITIDINE; RIMONABANT; ROSIGLITAZONE; SIBUTRAMINE; TESOFENSINE; TETRAHYDROLIPSTATIN; THALIDOMIDE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELNEPERIT; ZGN 433;

ANXIETY DISORDER; BARIATRIC SURGERY; BRAIN HEMORRHAGE; CALORIC INTAKE; CARDIOVASCULAR DISEASE; CATARACT; COUNSELING; DEPRESSION; DIET RESTRICTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENERGY EXPENDITURE; EPHEDRA; EUROPE; EXERCISE; FECES INCONTINENCE; FOOD DRUG INTERACTION; HEART OUTPUT; HUMAN; HYPERTENSION; HYPERTHERMIA; LIFESTYLE MODIFICATION; NEUROLOGIC DISEASE; OBESITY; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STEATORRHEA; STROKE; SUICIDAL IDEATION; UNITED STATES; VALVULAR HEART DISEASE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 79955040868     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2010.01353.x     Document Type: Review

References (30)

1. World Health Organization. Available from URL: Accessed 18 July 2010.
2. World Health Organization/International Obesity Task Force. The Asia-Pacific Perspective: Redefining Obesity and its Treatment. Australia: Health Communications Australia Pty Limited, 2000.
3. World Health Organization. Obesity and Overweight. Fact Sheet Number 311. 2006.
4. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-241.
5. World Health Organization Europe. 10 things you need to know about obesity. November 2006.
6. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.
7. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer and service-specific estimates. Health Aff 2009; 28: w822-w831.
8. Muller-Riemenschneider F, Reinhold T, Berghofer A, Willich SN. Health-economic burden of obesity in Europe. Eur J Epidemiol 2008; 23: 499-509.
9. Ostbye T, Dement JM, Krause KM. Obesity and workers' compensation: results from the Duke Health and Safety Surveillance System. Arch Intern Med 2007; 167: 766-773.
10. Neovius K, Johansson K, Kark M, Neovius M. Obesity status and sick leave: a systematic review. Obes Rev 2008; 10: 17-27.
11. Trogdon JG, Finkelstein EA, Hylans T, Dellea PS, Kamal-Bahl SJ. Indirect costs of obesity: a review of current literature. Obes Rev 2008; 9: 489-500.
12. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Available from URL: Accessed 18 July 2010.
13. American Diabetes Association. Standards of Medical Care in Diabetes-2010. Diabetes Care 2010; 33(Suppl 1): S11-S61.
14. International Diabetes Federation: Chapter 5, Lifestyle Management. Available from URL: Accessed 26 July 2010.
15. Kruger J, Galuska DA, Serdula MK, Jones DA. Attempting to lose weight: Specific practices among U.S. adults. Am J Prev Med 2004; 26: 402-406.
16. The U.S. Preventive Services Task Force, Screening for Obesity in Adults, Recommendations and Rationale. Available from URL: Accessed 5 November 2010.
17. FDA. Guidance for Industry: Developing Products for Weight Management. Available from URL: Accessed 18 July 2010.
18. EMA. Guideline on Clinical Evaluation of Medicinal Products Used in Weight Control. Available from URL: Accessed 18 July 2010.
19. Canoy D. Coronary heart disease and body fat distribution. Curr Atheroscler Rep 2010; 12: 125-133.
20. Phillips LK, Prins JB. The link between abdominal obesity and the metabolic syndrome. Curr Hypertens Rep 2008; 10: 156-164.
21. Caveney E, Turner JR. Regulatory landscapes for future antidiabetic drug development (Part I): FDA guidance on assessment of cardiovascular risks. J Clin Stud 2010; January Issue: 34-36.
22. Turner JR, Caveney E. Regulatory landscapes for future antidiabetic drug development (Part II): EMA guidance on assessment of cardiovascular risks. J Clin Stud 2010; March Issue: 38-40.
23. McCaughan M, Helbling L. The RPM Report 2010; 4: 1-11.
24. Durham TA, Turner JR. Introduction to Statistics in Pharmaceutical Clinical Trials. London: Pharmaceutical Press, 2008.
25. Food and Drug Administration, 2008. The Sentinel Initiative: National Strategy for Monitoring Medical Product Safety. Available from URL: Accessed 24 October 2010.
26. 110th US Congress. Food and Drug Administration Amendments Act; September 2007. Available from URL: Accessed 18 July 2010.
27. Faich G. Evaluation of REMS. Presentation given at the FDAnews/United BioSource Corporation/Center for Medicine in the Public Interest 'Drug Management and Drug Safety Summit'. Washington, DC: National Press Club, 29 October 2008.
28. Turner JR. Drug safety, medication safety, patient safety: an overview of recent FDA Guidances and initiatives. Regulatory Rapporteur 2009; 6: 4-8.
29. Sutter S, Davis J. FDA, EMA decisions on Avandia reflect the power of REMS. "The Pink Sheet:" Prescription Pharmaceuticals and Biotechnology. 27 September 2010; 1 and 4-6.
30. Turner JR. Integrated drug safety: benefit-risk assessments in drug development and use. Appl Clin Trials, in press.